These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1323 related items for PubMed ID: 24331749

  • 1. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.
    Vaccine; 2008 Jul 29; 26(32):4080-93. PubMed ID: 18550229
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
    Burger EA, Campos NG, Sy S, Regan C, Kim JJ.
    Vaccine; 2018 Aug 06; 36(32 Pt A):4823-4829. PubMed ID: 29807710
    [Abstract] [Full Text] [Related]

  • 13. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
    Kiatpongsan S, Kim JJ.
    PLoS One; 2014 Aug 06; 9(9):e106836. PubMed ID: 25198104
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N.
    Vaccine; 2015 May 07; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
    Ginsberg GM.
    Vaccine; 2013 Nov 22; 31 Suppl 8():I46-52. PubMed ID: 24229719
    [Abstract] [Full Text] [Related]

  • 16. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 17. Implementation of human papillomavirus immunization in the developing world.
    Kane MA, Serrano B, de Sanjosé S, Wittet S.
    Vaccine; 2012 Nov 20; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
    Abbas KM, van Zandvoort K, Brisson M, Jit M.
    Lancet Glob Health; 2020 Apr 20; 8(4):e536-e544. PubMed ID: 32105613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.